Lilly's baricitinib successful in late-stage dermatitis studies

|About: Eli Lilly and Company (LLY)|By:, SA News Editor

Two Phase 3 clinical trials, BREEZE-AD1 and BREEZE-AD2, evaluating Eli Lilly's (NYSE:LLY) baricitinib in adult patients with moderate-to-severe atopic dermatitis (AD) met the primary endpoints.

Both studies demonstrated that statistically significant proportions of patients in the treatment groups achieved at least two-point improvements and clear or almost clear skin as measured by a scale called IGA.

The results will be submitted for presentation at future medical conferences and for publication.

The company says these two trials are part of five studies that will support global marketing applications. Additional data should be available later this year.

Baricitinib, a JAK enzyme inhibitor, was approved in the U.S. for rheumatoid arthritis in June 2018. It is marketed under the brand name Olumiant.

Subscribe for full text news in your inbox